News
VCNX
7.41
-0.54%
-0.04
Vaccinex to raise $1.5M through in a direct offering
Vaccinex to raise $1.5M through in a direct offering of 193K shares and warrants. Shares in the company down 2.6% in pre-market trade. VCNX intends to use the net proceeds for working capital and general corporate purposes.
Seeking Alpha · 1d ago
Weekly Report: what happened at VCNX last week (0318-0322)?
Weekly Report · 4d ago
Weekly Report: what happened at VCNX last week (0311-0315)?
Weekly Report · 03/18 09:33
Weekly Report: what happened at VCNX last week (0304-0308)?
Weekly Report · 03/11 09:32
Weekly Report: what happened at VCNX last week (0226-0301)?
Weekly Report · 03/04 09:33
Weekly Report: what happened at VCNX last week (0219-0223)?
Weekly Report · 02/26 09:36
Health Care Sector Update for 02/21/2024: BLCO, TDOC, VCNX
NASDAQ · 02/21 18:54
Vaccinex Inc Broadens Reach with ActivMab® Technology Deals
TipRanks · 02/21 15:22
Teladoc Health, Avinger among healthcare movers
Healthcare On the Move: Teladoc Health, Avinger among healthcare movers. S&P 500 Health Care Sector -0.15% to 1685.75. Pharmaceuticals, Biotechnology & Life Science contributes 58% to index is down 0.18%.
Seeking Alpha · 02/21 15:00
Vaccinex Announces It Has Entered Into Eight New Antibody Discovery Agreements Integrating Use Of Its Proprietary ActivMAb Platform To Select Antibodies Against Difficult-To-Drug Transmembrane Protein Targets
Eight new antibody discovery agreements incorporate Vaccinex's powerful ActivMAb® Drug Discovery Platform ActivMab platform enables the discovery and development of high value antibodies against challenging multi-pass membrane targets. The company is pioneering a differentiated approach to treating Alzheimer's disease and cancer through SEMA4D.
Benzinga · 02/21 13:21
Weekly Report: what happened at VCNX last week (0212-0216)?
Weekly Report · 02/19 09:37
Why Vaccinex (VCNX) Stock Is Trading Lower
Vaccinex Inc announced a 1-for-14 reverse stock split effective February 19. The company's shares are trading lower by 7.1% to $0.79 Thursday morning. The action was approved by stockholders on February 8 to meet the Nasdaq Capital Market's minimum bid price requirement.
Benzinga · 02/15 14:31
Vaccinex Inc Announces Reverse Stock Split and Equity Adjustments
TipRanks · 02/15 13:22
Vaccinex, Inc. Announces 1-For-14 Reverse Stock Split
Vaccinex, Inc. Will effect a 1-for-14 reverse stock split of its common stock effective at 5:00 p.m. Eastern Time on Monday, February 19, 2024. The Company has until March 4, 2024 to comply with the $1.00 minimum bid price requirement of The Nasdaq Capital Market. Vaccinex is a clinical-stage biotechnology company pioneering a differentiated approach to treating neurodegenerative disease and cancer through the inhibition of SEMA4D.
Benzinga · 02/15 13:06
*Vaccinex Announces 1-for-14 Reverse Stock Split
Dow Jones · 02/15 13:00
12 Health Care Stocks Moving In Wednesday's After-Market Session
KalVista Pharma (NASDAQ:KALV) stock moved upwards by 11.0% to $15.99 during Wednesday's after-market session. The company's, Q4 earnings came out today. Anitra stock increased by 9.25% and CytoMed Therapeutics stock rose 7.5% in the same session. Beyond Air stock fell 8.11% and Adaptive Biotechnologies stock declined by 8.6%.
Benzinga · 02/14 21:31
Vaccinex Inc Stockholders Approve Reverse Stock Split
TipRanks · 02/13 21:43
Weekly Report: what happened at VCNX last week (0205-0209)?
Weekly Report · 02/12 09:33
12 Health Care Stocks Moving In Friday's After-Market Session
Singular Genomics Sys (NASDAQ:OMIC) shares moved upwards by 17.9% to $0.66 during Friday's after-market session. Vaccinex stock increased by 11.61% and Celularity shares rose by 7.52%. Intelligent Bio Solutions stock declined by 15.8% during the session.
Benzinga · 02/09 21:31
Vaccinex Clarifies No Intent for Equity Sales
TipRanks · 02/08 09:32
More
Webull provides a variety of real-time VCNX stock news. You can receive the latest news about Vaccinex Inc through multiple platforms. This information may help you make smarter investment decisions.
About VCNX
Vaccinex, Inc. is a clinical-stage biotechnology company. It discovers and develops targeted biotherapeutics to treat diseases with unmet medical needs, including cancer, neurodegenerative diseases and autoimmune disorders. Its platform technologies include SEMA4D antibody platform and ActivMAb antibody discovery platform. SEMA4D antibody platform is the application of its knowledge of SEMA4D biology to develop its lead product candidate pepinemab for the treatment of various diseases and conditions, including cancer and neuroinflammatory and neurodegenerative diseases. Pepinemab’s mechanisms of action block the SEMA4D signal and activate innate physiological mechanisms to respond to tumors or tissue injury. ActivMAb antibody discovery platform is a human antibody discovery platform based on a method for expressing multipass membrane proteins, as well as large and diverse libraries of high affinity, full-length human monoclonal antibodies on the surface of mammalian pox viruses.